Current Pharmaceutical Design

Author(s): Seyed H. Shahcheraghi, Venant Tchokonte-Nana, Marzieh Lotfi, Malihe Lotfi, Ahmad Ghorbani* and Hamid R. Sadeghnia*

DOI: 10.2174/1381612826666200131100630

DownloadDownload PDF Flyer Cite As
Wnt/beta-catenin and PI3K/Akt/mTOR Signaling Pathways in Glioblastoma: Two Main Targets for Drug Design: A Review

Page: [1729 - 1741] Pages: 13

  • * (Excluding Mailing and Handling)

Abstract

Glioblastoma (GBM) is the most common and malignant astrocytic glioma, accounting for about 90% of all brain tumors with poor prognosis. Despite recent advances in understanding molecular mechanisms of oncogenesis and the improved neuroimaging technologies, surgery, and adjuvant treatments, the clinical prognosis of patients with GBM remains persistently unfavorable. The signaling pathways and the regulation of growth factors of glioblastoma cells are very abnormal. The various signaling pathways have been suggested to be involved in cellular proliferation, invasion, and glioma metastasis. The Wnt signaling pathway with its pleiotropic functions in neurogenesis and stem cell proliferation is implicated in various human cancers, including glioma. In addition, the PI3K/Akt/mTOR pathway is closely related to growth, metabolism, survival, angiogenesis, autophagy, and chemotherapy resistance of GBM. Understanding the mechanisms of GBM’s invasion, represented by invasion and migration, is an important tool in designing effective therapeutic interventions. This review will investigate two main signaling pathways in GBM: PI3K/Akt/mTOR and Wnt/beta-catenin signaling pathways.

Keywords: Glioblastoma, cancer, molecular mechanisms, Wnt signaling pathway, PI3K/Akt/mTOR pathway, chemotherapy.